Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 25 April 2019, 14:13 HKT/SGT
Share:
    

Source: NEC Corporation
Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC
- Proceeds to Support Scaling and Advancement of Precision Medicine Computing Platform for Cancer Treatment -

TOKYO, Apr 25, 2019 - (JCN Newswire) - NEC Corporation (TSE: 6701) and BostonGene Corporation (BostonGene), a Boston, Mass-based biomedical software company, has announced a $50M series A strategic investment in BostonGene by NEC.

BostonGene, a pioneer in the use of biomedical software for advanced patient analysis, has discovered, developed, and patented a holistic approach to cancer treatment by defining the optimal therapy combination for individual patients, with a particular focus on immuno- and targeted therapies.

BostonGene's solution includes:

Genome and transcriptome sequencing methods to create a patient's molecular profile.
Algorithms that estimate the immune fitness and cancer characteristics of a patient.
A continuously updated expert-curated and Artificial Intelligence (AI)-driven database of cancer research and clinical information.

Cloud-native software that delivers a patient-prioritized list of best treatment options based on comprehensive data analysis of the tumor and its microenvironment.

Founded in 2015, BostonGene has evaluated its solution utilizing extensive data in close collaboration with many leading cancer centers across the U.S., and has a robust intellectual property portfolio.

The funding will allow BostonGene to accelerate its long-term strategy, enable the expansion of the company's development efforts, advance its collaboration programs, and support the growth of its talented and diverse team.

"As demonstrated by its remarkable growth and early widespread adoption, BostonGene is leading the precision medicine market in the innovation and development of a mission-critical computing platform," said Osamu Fujikawa, senior vice president and head of the Business Innovation Unit at NEC Corporation. "NEC and BostonGene share a common vision of the immense potential of an AI-driven approach to cancer immunotherapy. Leveraging the strengths of both companies we will be able to improve the survival rate and quality of life for cancer patients."

"Transforming and personalizing medicine, from treating a diagnosis to treating the person, is becoming a reality with BostonGene's unique breakthrough platform. Our early successes validate the market need and the potential of our solution to truly transform cancer treatment and dramatically improve patients' chances for survival and quality of life. An investment of this magnitude will support our vision, mission and strategy, as well as the formation of synergies with the NEC Health Tech business to create meaningful new opportunities," said Andrew Feinberg, President and CEO of BostonGene.

About BostonGene Corporation

BostonGene Corporation is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer. BostonGene's unique solution performs sophisticated analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. BostonGene's mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using advanced, personalized therapies. For more information, visit BostonGene at http://www.BostonGene.com.


About NEC Corporation

NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security efficiency and fairness of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at https://www.nec.com.

Contact:
NEC
Seiichiro Toda        
[email protected]
+81-3-3798-6511


Apr 25, 2019 14:13 HKT/SGT
Source: NEC Corporation

NEC Corporation (TSE: 6701)

Topic: Press release summary
Sectors: Enterprise IT, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation
Aug 23, 2019 10:42 HKT/SGT
NEC Receives Order for Intelligent Transportation System in Makkah, Saudi Arabia
Aug 21, 2019 10:24 HKT/SGT
NEC: Industrial Internet Consortium Approves Testbed of Negotiation Automation Platform for coordinating interests among AI systems
Aug 21, 2019 10:01 HKT/SGT
NEC to Install More than 20MW of Municipal Energy Storage Projects in New England
July 30, 2019 15:00 HKT/SGT
NEC Signs Sponsorship Agreement with MLB's Los Angeles Angels
July 30, 2019 14:00 HKT/SGT
NEC Begins Shipping 5G Radio Equipment to DOCOMO
July 29, 2019 16:49 HKT/SGT
NEC Acquires Norwegian Bioinformatics Company, OncoImmunity AS
July 26, 2019 19:13 HKT/SGT
Star Alliance and NEC Corporation Sign Partnership Agreement to Enhance Passenger Experience through Biometric Data Recognition Technology
July 25, 2019 09:54 HKT/SGT
NEC Provides Smart City Solutions in Cordoba, Spain
July 19, 2019 14:13 HKT/SGT
NEC: Autonomous Backhoe Operation System Improves the Productivity and Safety of Construction Sites
July 17, 2019 09:03 HKT/SGT
NEC Provides Facial Recognition System for Admission Control at EU Summit
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: